In a groundbreaking study recently published in the Journal of Medicinal Chemistry, researchers have taken a major step forward in addressing this limitation by chemically modifying psilocin, the active metabolite of psilocybin. The team, led by Andrea Mattarei, Sara De Martin, and Paolo Manfredi, successfully synthesized a series of novel psilocin derivatives designed to maintain the compound’s therapeutic serotonergic activities while substantially reducing the hallucinogenic side effects. Their approach centered on engineering fluorinated reversible N-alkyl carbamate derivatives, offering controlled release and enhanced metabolic stability.

Central to the scientific rationale behind this work is the dissociation between the serotonergic receptor activation, which mediates therapeutic effects, and the hallucinogenic outcome typically associated with psychedelic compounds. This distinction has vital implications: it may allow for the design of treatments that leverage the beneficial mood- and cognition-altering properties of psilocin without triggering intense psychedelic experiences. This ‘sub-hallucinogenic’ profile could revolutionize treatment paradigms for psychiatric conditions by improving safety and patient compliance.

The genesis of these new compounds involved meticulous chemical synthesis aimed at circumventing rapid metabolism and absorption issues that plague native psilocin. The researchers created five derivatives, each with tailored carbamate functionalities that could gradually release active psilocin molecules upon administration. In vitro testing with human plasma and simulated gastrointestinal environments demonstrated that one compound—denoted as 4e—exhibited superior pharmacokinetic properties, including enhanced stability during digestion and a prolonged release profile.

Pharmacodynamic evaluations revealed that 4e sustained comparable affinity and activity at serotonin receptor subtypes implicated in mood regulation, particularly 5-HT2A receptors. This receptor subset is widely understood to mediate both therapeutic and hallucinogenic effects of classic psychedelics. The sustained receptor engagement by 4e contrasts with the rapid peak levels typically observed with unmodified psilocin, suggesting that controlled delivery can modulate the overall pharmacological impact.

In vivo studies in murine models provided compelling evidence supporting the therapeutic promise of 4e. When administered orally, 4e demonstrated effective brain penetration, crossing the blood-brain barrier efficiently. Importantly, over a 48-hour period, psilocin levels in the brain exhibited a lower peak but more sustained presence compared to equivalent doses of pharmaceutical-grade psilocybin. Behavioral assays further corroborated these findings: animals receiving 4e exhibited significantly reduced head-twitch responses, which are established proxies for psychedelic or hallucinogenic activity in rodents.

The attenuated head-twitch behavior in mice suggests that 4e minimizes acute psychedelic effects without compromising central nervous system penetration or receptor engagement. This pharmacokinetic and pharmacodynamic profile reinforces the hypothesis that saturating serotonin receptors steadily and at lower concentrations may achieve desired therapeutic outcomes with reduced risk of hallucinations or other mind-altering side effects.

From a medicinal chemistry perspective, the introduction of fluorine atoms into the N-alkyl carbamate moiety not only improved metabolic stability by resisting enzymatic degradation but also enhanced compound lipophilicity, contributing to efficient blood-brain barrier permeation. Such chemical modifications are a sophisticated strategy in drug design to optimize both bioavailability and controlled drug release within target tissues, crucial for maximizing therapeutic index.

The synthesis and pharmacological exploration of these psilocin derivatives open new frontiers in psychedelic drug development. By decoupling therapeutic serotonin receptor modulation from hallucinogenic effects, these findings pave the way for safer, more acceptable treatments for complex brain disorders. The implications extend beyond mood disorders and include potential applications in neurodegenerative diseases such as Alzheimer’s, where serotonergic dysregulation contributes to pathophysiology.

Despite the promising results, the researchers emphasize the necessity of further studies to elucidate the exact mechanistic underpinnings and long-term safety profiles of these compounds in humans. Comprehensive clinical trials will be essential to translate these preclinical successes into effective therapeutic agents. Additionally, understanding how sub-hallucinogenic serotonergic modulation correlates with clinical efficacy across diverse psychiatric and neurological disorders remains a critical area for continued research.

This study was supported by funding from MGGM Therapeutics, LLC, in collaboration with NeuroArbor Therapeutics Inc. Multiple authors also disclosed their involvement as inventors on patents related to these innovative psilocin derivatives, highlighting both scientific and translational significance within the pharmaceutical landscape.

In conclusion, the development of fluorinated reversible N-alkyl carbamate derivatives of psilocin such as compound 4e marks a significant stride in psychedelic medicinal chemistry. These compounds offer a novel approach to harnessing the molecular benefits of psilocybin without incurring the substantial psychotropic side effects that have historically limited its clinical use. The reported pharmacokinetic profiles and behavioral data in animal models provide a solid foundation for continued exploration aimed at expanding and refining neuropsychiatric treatment options.

By overcoming the classic trade-off between therapeutic potential and adverse psychedelic effects, this research underscores how innovative chemical engineering can transform the future of mental health pharmacotherapy, aligning with the aspirations of precision medicine and patient-centered care.

Subject of Research:
Article Title: Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible N-Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain Exposure
News Publication Date: 26-Feb-2026
Web References: http://dx.doi.org/10.1021/acs.jmedchem.5c01797

Keywords

Psilocybin, Psilocin, Fluorinated Derivatives, N-Alkyl Carbamate, Serotonin Receptors, 5-HT2A, Neuropsychiatric Disorders, Sub-Hallucinogenic, Pharmacokinetics, Neurodegenerative Diseases, Mood Disorders, Drug Design

The research tackles a core challenge in neuroscience: understanding how transient pharmacological interventions can induce lasting changes in brain function that translate into behavioral modifications. Behavioral flexibility—the capacity to modify responses based on environmental demands—is impaired in numerous psychiatric conditions such as PTSD, addiction, and obsessive-compulsive disorder. These disorders often feature perseverative fear responses, where extinction of learned fearful memories is hindered. By examining psilocybin’s impact at the level of individual neurons within a critical brain region known as the retrosplenial cortex (RSC), Rogers and colleagues moved beyond behavioral observation to reveal cellular underpinnings of therapeutic change.

Leveraging cutting-edge longitudinal single-cell calcium imaging techniques in murine models, the study involved a five-day trace fear learning and extinction paradigm, a sophisticated assay that models the acquisition and subsequent suppression of conditioned fear responses. This approach enabled researchers to record the activity of the same populations of neurons over several days, capturing the dynamic shifts in neural ensemble activity triggered by psilocybin administration. The retrosplenial cortex, an area implicated in integrating contextual and spatial information with emotional processing, served as a strategic focus due to its emerging importance in modulating flexible responses to fear.

The findings revealed that a single psilocybin dose induced pronounced turnover in cortical neural ensembles within the RSC, effectively restructuring the balance of neuron populations activated during fear and extinction phases. Specifically, psilocybin concurrently suppressed the activity of neurons associated with the expression of fear (fear-active neurons) and recruited new neurons linked with fear extinction (extinction-active neurons). This bidirectional modulation created an enhanced neural environment conducive to the suppression of maladaptive fear behaviors, reflected behaviorally in accelerated fear extinction.

Such dualistic modulation underscores a critical insight: therapeutic effects do not merely stem from dampening aberrant activity but also from promoting the engagement of alternative, adaptive circuits. The notion that psilocybin triggers neuronal recruitment—effectively “rewiring” cortical ensembles—provides a tangible neurobiological framework for the drug’s long-lasting efficacy. The shift in population dynamics within the retrosplenial cortex was predictive of behavioral outcomes, crystallizing the link between microscale changes in neural activity and macroscale changes in learned behavior.

Complementing the empirical data, the study employed a computational modeling approach to simulate the microcircuit dynamics observed experimentally. In this model, simulated fear-active units were inhibited, which in turn modulated the recruitment of extinction-active units and influenced behavioral variability in freezing—the hallmark measure of fear in rodent models. This computational framework not only recapitulated the experimental findings but also provided mechanistic insight into how specific circuit perturbations result in behavioral shifts. It suggests that psilocybin’s effects emerge from orchestrated, circuit-level interactions rather than isolated changes in singular neurons.

These revelations hold profound implications for the future of psychiatric therapeutics. By elucidating how psilocybin orchestrates the opposing modulation of distinct neuronal ensembles within a key cortical hub, the study offers a blueprint for targeting dynamic circuit flexibility as a mechanism for remedying behavioral inflexibility. The retrosplenial cortex, previously underappreciated in the context of fear extinction, is spotlighted here as a potential locus for intervention in trauma-related disorders.

Furthermore, the longitudinal recording method highlights the importance of studying neuronal populations across time frames congruent with therapy courses. This temporal resolution is critical for understanding sustained, rather than transient, neuroplastic changes—vital for addressing chronic conditions that involve ingrained maladaptive behaviors. Psilocybin’s rapid induction of ensemble turnover challenges traditional perspectives on neural plasticity, proposing that short-lived drug exposure can produce enduring cortical remodeling.

This study also fuels the broader discourse on the intersection of psychedelics and neuroplasticity. Previous investigations have implicated psychedelics in promoting synaptogenesis and dendritic spine growth; however, the current research extends these findings to functional network reshaping within physiologically relevant behavioral paradigms. By linking ensemble dynamics to behavioral flexibility, the research bridges a critical gap between structural plasticity and functional outcomes.

Clinically, the work lays a foundational neurobiological rationale for observed psilocybin-assisted psychotherapy benefits in clinical trials targeting PTSD, depression, and related disorders. Understanding the cellular and circuit-level basis of treatment advances toward optimally timed dosing and integration with behavioral interventions, maximizing therapeutic efficacy. The dual action of suppression and recruitment in the RSC may inform combination therapies that synergize pharmacological agents with behavioral extinction protocols.

Notably, the findings pose intriguing questions about the specificity of circuit modulation. How does psilocybin selectively target fear-active versus extinction-active neurons? Are receptor-specific pathways or network connectivity determinants of this specificity? Future studies might explore receptor subtype contributions, possibly implicating serotonergic 5-HT2A receptors widely known to mediate psychedelic effects, and map broader cortical-subcortical interactions involved in fear circuit remodeling.

In sum, this investigation marks a pivotal advance in deciphering the mechanistic substrates through which psilocybin mediates sustained behavioral change. By charting the dynamic, bidirectional modulation of retrosplenial cortical ensembles, Rogers and colleagues provide compelling evidence that psychedelic-induced plasticity operates at the level of precise neural ensembles, recalibrating the balance between fear expression and extinction. This nuanced understanding of microcircuit flexibility enriches conceptual frameworks of psychiatric treatment and paves the way for rational design of next-generation therapeutics targeting resilient maladaptive behaviors.

As the global conversation surrounding psychedelics shifts from stigma to scientific rigor, efforts like this underscore the critical need for integrative research combining behavioral neuroscience, systems neurophysiology, computational modeling, and clinical translation. Unlocking the multidimensional effects of substances like psilocybin holds promise not only for mental health breakthroughs but also for expanding foundational knowledge of brain circuit adaptability and learning.

Looking ahead, integrating this line of inquiry with human neuroimaging studies and longitudinal patient outcomes will be crucial to validate and refine mechanistic models. The nuanced interplay of neural ensembles revealed in mouse retrosplenial cortex serves as a valuable scaffold for such translational efforts. Ultimately, deciphering how pharmacologically induced circuit rewiring fosters enduring behavioral flexibility may revolutionize the approach to neuropsychiatric disease treatment—transforming therapeutic landscapes and improving countless lives.

Subject of Research: Neural circuit mechanisms underlying psilocybin-enhanced behavioral flexibility and fear extinction in the retrosplenial cortex of mice.

Article Title: Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles.

Article References:
Rogers, S.A., Heller, E.A. & Corder, G. Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles.
Nat Neurosci (2025). https://doi.org/10.1038/s41593-025-01964-9

Image Credits: AI Generated